Advanced Parkinson's Disease
Conditions
Keywords
carbidopa, levodopa-carbidopa, levodopa, levodopa/carbidopa suspension, dyskinesia, Duodopa, levodopa-carbidopa intestinal gel, Severe Motor Fluctuations, DUOPA
Brief summary
The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.
Detailed description
Study S187.3.001 (NCT00357994) and Study S187.3.002 (NCT00660387) were 2 identically designed, Phase 3, 12-week, randomized, double-blind, double-dummy, parallel-group, multicenter studies recruiting subjects from distinct sites. These studies evaluated the efficacy, safety, and tolerability of levodopa-carbidopa intestinal gel (LCIG) in the treatment of levodopa-responsive subjects with advanced PD who had persistent severe motor fluctuations, despite optimized treatment with oral levodopa-carbidopa, concomitant with other available antiparkinsonian medications. Participants were randomized to either LCIG active gel + placebo capsules or levodopa-carbidopa immediate release (IR) active capsules + placebo gel. Both treatment arms received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration, active LCIG or placebo gel. Data from these 2 studies were combined for analysis. The decision to combine the study data for analysis was made before enrollment was completed for both studies.
Interventions
infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
DRUGPlacebo gel
DRUGLevodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
DEVICEPEG tube
percutaneous endoscopic gastrostomy tube
DEVICEJ-tube
jejunal tube
Sponsors
Quintiles, Inc.
AbbVie (prior sponsor, Abbott)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria * Levodopa-responsive participants who demonstrate some identifiable 'on response,' established by Investigator observation * Demonstrate severe motor fluctuations in spite of individually optimized treatment and where therapy options are indicated
Exclusion criteria
* Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism * Undergone surgery for the treatment of PD * Contraindications to levodopa * Subjects with any neurological deficit that may interfere with the study assessments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline to Week 12 in Average Daily Normalized Off Time | Baseline, Week 12 | Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for off time indicates improvement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Average Daily Normalized On Time Without Troublesome Dyskinesia at Week 12 | Baseline, Week 12 | Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. On time without troublesome dyskinesia (involuntary muscle movement) is defined as on time without dyskinesia and on time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for on time without troublesome dyskinesia indicates improvement. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms. |
| Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12 | Baseline, Week 12 | The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability. |
| Change From Baseline in UPDRS Part III Score at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability. |
| Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12 | Baseline, Week 12 | The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement. |
| Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12 | Baseline, Week 12 | The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=Never, 1=Rarely, 2=Sometimes, 3=Quite frequently, and 4= Nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver. |
| Change From Baseline in Average Daily Normalized On Time With Troublesome Dyskinesia at Week 12 | Baseline, Week 12 | Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Employment Impairment (EMP) II Status at Week 12 | Week 12 (or early termination) | The EMP instruments are designed to collect information regarding employment and ability to run a household. EMP I questions include: Are you currently in paid employment? (If yes, at which percentage have you been working during the last 4 weeks?); Have you got someone to run your household for you? (If yes, how much time per week does he/she spend in your household?); Are you retired? (If yes, for which reason?) The retirement question (from EMP I) is excluded from the EMP II instrument. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability. |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability. |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. Questions 32, 33, and 34 on UPDRS Part IV were totaled to evaluate dyskinesias. Each of these questions is measured on a 5-point scale (0-4). The Part IV dyskinesia score will range from 0-12 and higher scores are associated with more disability. |
| Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12 | Baseline, Week 12 | The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 no disability. |
| Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12 | Baseline, Week 12 | The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.' |
| Employment Impairment (EMP) I Status at Baseline | Baseline | The EMP instruments are designed to collect information regarding employment and ability to run a household. EMP I questions include: Are you currently in paid employment? (If yes, at which percentage have you been working during the last 4 weeks?); Have you got someone to run your household for you? (If yes, how much time per week does he/she spend in your household?); Are you retired? (If yes, for which reason?). |
| Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12 | Baseline, Week 12 | The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness. |
Countries
Germany, United States
Participant flow
Pre-assignment details
Studies S187.3.001 (NCT00357994) and S187.3.002 (NCT00660387) were 2 identically designed, Phase 3, 12-week, randomized, double-blind, double-dummy, parallel-group, multicenter studies recruiting subjects from distinct sites. All study information and results presented reflect the study data and analyses for the two studies combined.
Participants by arm
| Arm | Count |
|---|---|
| LCIG + Placebo Capsules Participants were randomized to Levodopa-Carbidopa Intestinal Gel (LCIG; levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG. | 37 |
| Placebo Gel + Levodopa-Carbidopa Capsules Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo. | 34 |
| Total | 71 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 |
| Overall Study | Lack of Efficacy | 0 | 1 |
| Overall Study | Protocol Violation | 1 | 0 |
Baseline characteristics
| Characteristic | LCIG + Placebo Capsules | Placebo Gel + Levodopa-Carbidopa Capsules | Total |
|---|---|---|---|
| Age, Continuous | 63.7 years STANDARD_DEVIATION 9.5 | 65.1 years STANDARD_DEVIATION 6.8 | 64.4 years STANDARD_DEVIATION 8.3 |
| Age, Customized <65 years | 21 participants | 15 participants | 36 participants |
| Age, Customized >=65 years | 16 participants | 19 participants | 35 participants |
| Sex: Female, Male Female | 13 Participants | 12 Participants | 25 Participants |
| Sex: Female, Male Male | 24 Participants | 22 Participants | 46 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 35 / 37 | 34 / 34 |
| serious Total, serious adverse events | 5 / 37 | 7 / 34 |
Outcome results
Primary
Change From Baseline to Week 12 in Average Daily Normalized Off Time
Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for off time indicates improvement.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline to Week 12 in Average Daily Normalized Off Time | -4.04 hours | Standard Error 0.65 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline to Week 12 in Average Daily Normalized Off Time | -2.14 hours | Standard Error 0.66 |
p-value: 0.001595% CI: [-3.05, -0.76]ANCOVA
Secondary
Change From Baseline in Average Daily Normalized On Time Without Troublesome Dyskinesia at Week 12
Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. On time without troublesome dyskinesia (involuntary muscle movement) is defined as on time without dyskinesia and on time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for on time without troublesome dyskinesia indicates improvement.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Average Daily Normalized On Time Without Troublesome Dyskinesia at Week 12 | 4.11 hours | Standard Error 0.75 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Average Daily Normalized On Time Without Troublesome Dyskinesia at Week 12 | 2.24 hours | Standard Error 0.76 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.005995% CI: [0.56, 3.17]ANCOVA
Secondary
Change From Baseline in Average Daily Normalized On Time With Troublesome Dyskinesia at Week 12
Based on the Parkinson's Disease Symptom Diary. On time is when PD symptoms are well controlled by the drug. Off time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Average Daily Normalized On Time With Troublesome Dyskinesia at Week 12 | -0.11 units on a scale | Standard Error 0.52 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Average Daily Normalized On Time With Troublesome Dyskinesia at Week 12 | -0.03 units on a scale | Standard Error 0.52 |
p-value: 0.857495% CI: [-0.98, 0.82]ANCOVA
Secondary
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12 | 5.2 units on a scale | Standard Error 4.3 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12 | -6.3 units on a scale | Standard Error 4.3 |
p-value: 0.003395% CI: [4, 18.9]ANCOVA
Secondary
Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12
The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12 | 0.054 units on a scale | Standard Error 0.043 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12 | -0.016 units on a scale | Standard Error 0.043 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.06795% CI: [-0.005, 0.146]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12 | -12.9 units on a scale | Standard Error 5.3 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12 | -1.3 units on a scale | Standard Error 5.2 |
p-value: 0.012995% CI: [-20.6, -2.5]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12 | -13.5 units on a scale | Standard Error 6.1 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12 | -10.2 units on a scale | Standard Error 6 |
p-value: 0.521395% CI: [-13.6, 6.9]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12 | -7.3 units on a scale | Standard Error 4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12 | -3.2 units on a scale | Standard Error 3.9 |
p-value: 0.240795% CI: [-10.8, 2.8]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12 | -9.5 units on a scale | Standard Error 4.1 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12 | 4.4 units on a scale | Standard Error 4.1 |
p-value: 0.000295% CI: [-20.8, -6.8]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12 | -7.1 units on a scale | Standard Error 4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12 | -4.9 units on a scale | Standard Error 4 |
p-value: 0.524695% CI: [-9, 4.6]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12 | -17.3 units on a scale | Standard Error 5 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12 | -6.8 units on a scale | Standard Error 4.9 |
p-value: 0.018495% CI: [-19.1, -1.8]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12 | -3.9 units on a scale | Standard Error 3.5 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12 | -0.1 units on a scale | Standard Error 3.6 |
p-value: 0.224395% CI: [-9.9, 2.4]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12 | -8.9 units on a scale | Standard Error 4.4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12 | -4.5 units on a scale | Standard Error 4.4 |
p-value: 0.242395% CI: [-12, 3.1]ANCOVA
Secondary
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12 | -10.9 units on a scale | Standard Error 3.3 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12 | -3.9 units on a scale | Standard Error 3.2 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.015595% CI: [-12.6, -1.4]ANCOVA
Secondary
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12 | -1.8 units on a scale | Standard Error 1.3 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12 | 1.3 units on a scale | Standard Error 1.3 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.008695% CI: [-5.3, -0.8]ANCOVA
Secondary
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment. No missing data was imputed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12 | -0.2 units on a scale | Standard Error 0.4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12 | -0.5 units on a scale | Standard Error 0.4 |
p-value: 0.374195% CI: [-0.4, 0.9]ANCOVA
Secondary
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. Questions 32, 33, and 34 on UPDRS Part IV were totaled to evaluate dyskinesias. Each of these questions is measured on a 5-point scale (0-4). The Part IV dyskinesia score will range from 0-12 and higher scores are associated with more disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment. No missing data was imputed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12 | 0.4 units on a scale | Standard Error 0.5 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12 | 0.8 units on a scale | Standard Error 0.5 |
p-value: 0.357895% CI: [-1.1, 0.4]ANCOVA
Secondary
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12 | -1.1 units on a scale | Standard Error 0.7 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12 | 0.1 units on a scale | Standard Error 0.7 |
p-value: 0.036195% CI: [-2.4, -0.1]ANCOVA
Secondary
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 no disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12 | -3.6 units on a scale | Standard Error 3.4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12 | -2.1 units on a scale | Standard Error 3.4 |
p-value: 0.608895% CI: [-7.4, 4.4]ANCOVA
Secondary
Change From Baseline in UPDRS Part III Score at Week 12
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in UPDRS Part III Score at Week 12 | -1.5 units on a scale | Standard Error 2.4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in UPDRS Part III Score at Week 12 | -2.9 units on a scale | Standard Error 2.4 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.50295% CI: [-2.8, 5.6]ANCOVA
Secondary
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12
The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=Never, 1=Rarely, 2=Sometimes, 3=Quite frequently, and 4= Nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| LCIG + Placebo Capsules | Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12 | -2.8 units on a scale | Standard Error 3.7 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12 | 1.7 units on a scale | Standard Error 3.3 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.150195% CI: [-10.7, 1.7]ANCOVA
Secondary
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Time frame: Baseline, Week 12
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| LCIG + Placebo Capsules | Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12 | CGI-I at Week 12 | 2.3 units on a scale | Standard Deviation 1.2 |
| LCIG + Placebo Capsules | Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12 | CGI-S at Baseline | 4.2 units on a scale | Standard Deviation 0.7 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12 | CGI-I at Week 12 | 3.2 units on a scale | Standard Deviation 1.4 |
| Placebo Gel + Levodopa-Carbidopa Capsules | Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12 | CGI-S at Baseline | 4.6 units on a scale | Standard Deviation 0.8 |
Comparison: Since the null hypothesis for the primary analysis was rejected in favor of the alternative hypothesis, hierarchical testing was performed for secondary variables on the Full Analysis data set at the 0.50 level using a gatekeeping procedure to preserve family-wise error rate.p-value: 0.025895% CI: [-1.4, -0.1]ANCOVA
Secondary
Employment Impairment (EMP) II Status at Week 12
The EMP instruments are designed to collect information regarding employment and ability to run a household. EMP I questions include: Are you currently in paid employment? (If yes, at which percentage have you been working during the last 4 weeks?); Have you got someone to run your household for you? (If yes, how much time per week does he/she spend in your household?); Are you retired? (If yes, for which reason?) The retirement question (from EMP I) is excluded from the EMP II instrument.
Time frame: Week 12 (or early termination)
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment. Missing data was not imputed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | Someone Else Runs the Household (SRH)=Yes | 22 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 50% of Past 4 Weeks | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 100% of Time per Week | 13 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 25% of Past 4 Weeks | 0 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 75% of Time per Week | 5 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | Paid Employment (PE)=Yes | 10 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 50% of Time per Week | 0 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, Other % of Past 4 Weeks | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 25% of Time per Week | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 75% of Past 4 Weeks | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, Other % of Time per Week | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=No | 25 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=No | 13 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 100% of Past 4 Weeks | 6 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=No | 7 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | Paid Employment (PE)=Yes | 5 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 100% of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 75% of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 25% of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, Other % of Past 4 Weeks | 0 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=No | 26 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | Someone Else Runs the Household (SRH)=Yes | 24 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 100% of Time per Week | 12 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 75% of Time per Week | 4 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 50% of Time per Week | 4 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, 25% of Time per Week | 2 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | SRH=Yes, Other % of Time per Week | 2 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) II Status at Week 12 | PE=Yes, 50% of Past 4 Weeks | 2 participants |
Secondary
Employment Impairment (EMP) I Status at Baseline
The EMP instruments are designed to collect information regarding employment and ability to run a household. EMP I questions include: Are you currently in paid employment? (If yes, at which percentage have you been working during the last 4 weeks?); Have you got someone to run your household for you? (If yes, how much time per week does he/she spend in your household?); Are you retired? (If yes, for which reason?).
Time frame: Baseline
Population: Full Analysis Set: randomized participants who had the study device implanted and had data for baseline and at least 1 post-baseline assessment. Missing data was not imputed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 75% of Past 4 Weeks | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 50% of Time per Week | 3 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, Other % of Past 4 Weeks | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 25% of Time per Week | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 100% of Past 4 Weeks | 6 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, Other % of Time per Week | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=No | 25 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=No | 11 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 50% of Past 4 Weeks | 0 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | Are You Retired (R)=Yes | 24 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | Someone Else Runs the Household (SRH)=Yes | 24 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Old Age Pensioner | 8 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | Paid Employment (PE)=Yes | 10 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Premature Due to PD | 13 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 100% of Time per Week | 15 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Premature Due to Other Condition | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 25% of Past 4 Weeks | 1 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Other Reason | 2 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 75% of Time per Week | 3 participants |
| LCIG + Placebo Capsules | Employment Impairment (EMP) I Status at Baseline | R=No | 11 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 75% of Time per Week | 4 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | Paid Employment (PE)=Yes | 8 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 100% of Past 4 Weeks | 3 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 75% of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 50% of Past 4 Weeks | 2 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, 25% of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=Yes, Other % of Past 4 Weeks | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | PE=No | 23 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | Someone Else Runs the Household (SRH)=Yes | 25 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 100% of Time per Week | 13 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | R=No | 8 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 50% of Time per Week | 5 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, 25% of Time per Week | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=Yes, Other % of Time per Week | 2 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | SRH=No | 6 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | Are You Retired (R)=Yes | 23 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Old Age Pensioner | 8 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Premature Due to PD | 12 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Premature Due to Other Condition | 1 participants |
| Placebo Gel + Levodopa-Carbidopa Capsules | Employment Impairment (EMP) I Status at Baseline | R=Yes, Other Reason | 2 participants |